Answers are grounded in this paper and cite their sources.
Prospective study shows differing outcomes of radiotherapy in metastatic breast cancer subtypes, suggesting tailored approaches.
Luminal subtypes have better local control and progression-free survival post-HPRT compared to TNBC and HER2+ subtypes, which can further be used to stratify radiotherapy fractionation schedules.
No takes yet. Share an insight, caveat, or question.
Thimmaiah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: